Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions

23.12.2025 20:51:00 CET | Business Wire | Press Release

Share

Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach.

The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process for innovation.

This process begins with AI Create, a discovery and validation engine that uses internal AI tools for trend monitoring and horizon scanning. Validated concepts then transition immediately into AI Forge, the building and scaling engine. AWAKE is built upon core pillars—AI-first thinking, Global Integration, and Shared Infrastructure—that work in tandem to eliminate the traditional frictions of the startup lifecycle. By prioritising opportunities where autonomous agents and foundational models provide a 10x competitive advantage, AWAKE ensures every project has an AI-native DNA. This is amplified by a global operational structure that leverages distributed technology hubs in Chicago, Madrid, and Tbilisi, ensuring that ventures are born with a global value proposition and access to international talent from day one. By utilising a centralised infrastructure backbone, AWAKE drastically reduces the time and resources required for launch, allowing talent to focus relentlessly on disruption and market leadership.

A Declaration of Intent for the AI Era

"AWAKE is more than a venture studio; it is a declaration of intent to industrialise the next generation of AI-native solutions," said José Antonio Martínez Aguilar, CEO and Founder of Making Science. "We have already seen the impact of this model within our own walls. By establishing this repeatable engine, we are freeing entrepreneurial talent to focus relentlessly on scale. Whether we are forging a new internal tool or a global startup, Making Science’s expertise in data and AI is the backbone of that evolution."

About Making Science

Making Science is a global company specialising in digital acceleration, currently employing over 1,200 people and with a presence and technological development in 17 markets: Spain, Portugal, Mexico, Colombia, Argentina, Brazil, France, Italy, the United Kingdom, Ireland, Sweden, Denmark, Norway, Finland, Germany, Georgia, and the USA. As a consulting partner of Local Planet, the world's largest network of independent media agencies, Making Science develops technological solutions and offers digital marketing, Adtech and Martech, cloud technologies and software, and cybersecurity services globally, through delivery hubs that drive job creation and the availability of highly qualified technology talent.

Making Science comprises four business lines: the Global Digital Agency with Technology, offering 360 digital advertising services that integrate strategic planning, creativity, data, and technology; RAISING, the Technology and Innovation Division, which combines business expertise with data science to offer advanced AI-based marketing solutions; AWAKE, a Venture Studio that industrializes the creation of AI-First startups and business solutions; and the Investment Area of ​​Making Science, with Ventis and TMQ, as a business diversification line and implementation of the capabilities of all areas of Making Science.

With RAISING, the technology division, the company positions itself as a global leader in innovation and digital transformation. Thanks to its ad-machina technology solution, which operates as an Agentic AI Marketing Platform, and the use of tools such as Trust Generative AI and Gauss AI, brands maximise their business results through Artificial Intelligence.

In addition, the company participates in various ESG initiatives, including the Climate Pledge, the United Nations Global Compact, and the Pledge1% initiative, supporting non-profit organisations in its community with a strong commitment to achieving a positive impact on society.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251223642786/en/

Contacts

Press Contacts
Linda Cureton - makingscience@teamgingermay.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press Release

Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s Radio City Music Hall and Intuit Dome in California. “People are seeking richer and more immersive e

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6 The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press Release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press Release

The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press Release

VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye